Medicare expands coverage for rare genetic lung disease, but leaves MA plan members behind
H.R. 2343 — John W. Walsh Alpha-1 Home Infusion Act of 2025 · Filed by Maria Salazar (R-FL) · 55 cosponsors · Introduced Mar 25, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends Medicare to cover Alpha-1 Antitrypsin Deficiency (a rare genetic lung disease) treatment delivered at home, specifically augmentation therapy administered by qualified home infusion suppliers. Medicare will pay 80% of the cost of intravenous administration kits and up to 2 hours of nursing care per treatment session for eligible beneficiaries enrolled in Medicare Parts A and B (but not Medicare Advantage plans), effective January 1, 2027.
Why we flagged it
The bill's core function is straightforward: adding a specific treatment modality (home infusion augmentation therapy for Alpha-1 Antitrypsin Deficiency) to Medicare's covered services. This is a standard coverage amendment, not a deregulation, subsidy carve-out, or liability shield.
What the text implies
- The restriction to Parts A/B beneficiaries (excluding Medicare Advantage enrollees) may create a two-tier system where MA plan members cannot access this covered treatment through their plans, potentially incentivizing disenrollment or creating access gaps for MA beneficiaries with Alpha-1 deficiency.
- Payment is made directly to qualified home infusion therapy suppliers, not to beneficiaries or providers, concentrating reimbursement power with a specific vendor class and potentially creating barriers to entry for smaller or non-traditional suppliers.
The full analysis lists 4 implications of this text.
Who stands to gain
home infusion therapy suppliers; pharmaceutical manufacturers of Alpha-1 Proteinase Inhibitor products; nursing service providers